secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2026-02-23T23:59:59+00:00
Accession:  0001104659-26-018333
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia
------------------------------------------------------------------------

- AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.
- QIDP provides five-year Hatch-Waxman market exclusivity extension and eligibility for Fast Track.
- CEO Dr. Deborah Birx says Phase 3 superiority study planned to start in H2 2026.
- Company intends to submit a request for Fast Track Designation for AP-SA02 to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465926018333/0001104659-26-018333-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465926018333/tm267017d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018333

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer